seed
Stage
2024
Founded
3
Investors
About
Nuntius Therapeutics develops transformative mRNA therapies by leveraging proprietary delivery technology, machine learning and superior nucleic acid engineering. The company utilizes programmable, non-immunogenic nanocarriers capable of superior tissue and cell targeting beyond the liver.
Explore Nuntius Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.